Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial ...
Study findings provide new tools to assess treatment preferences when using hypomethylating agents in myelodysplastic syndromes (MDS). The study aimed to develop the TPMQ for clinicians (mTPMQ), ...
Please provide your email address to receive an email when new articles are posted on . Most patients with newly diagnosed high-risk myelodysplastic syndrome do not receive guideline-recommended ...
Dr. Inga Hofman Zhang from the University of Wisconsin School of Medicine provides an update on treating MDS in children. Dr. Naval Daver from MD Anderson Cancer Center talks about the relationship ...
Patients with MDS report more symptoms than physicians, indicating a communication gap in symptom assessment. Allogeneic hematopoietic stem cell transplantation is the only cure but is limited to ...
Younger patients with relapsed MDS may benefit from DLI post-stem cell transplant, improving overall survival rates. DLI is associated with graft-versus-host disease, but its impact on prognosis is ...
Social worker Marie Brewer talks about the challenges of supporting a loved one with myelodysplastic syndrome (MDS) and ways to find assistance and treatment options. Myelodysplastic syndromes (MDS) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results